Scienceletter

SOLVO Biotechnology believes in open and timely communication with its customers, research and business partners, investors and the financial community. Please view our press releases for a more detailed view of our company's development:

Implications of BCRP in disease modifying anti-rheumatic drugs (DMARD) resistance: the example of Leflunomide and its active metabolite - 01 July 2008

Cholesterol on the rescue: improved membrane assay for HT screening of ABCG2 transporter - drug interactions - 11 June 2007

Third Scienceletter: In Vitro ABC Transporter Assays for Nutrient Absorption and Drug-Nutrient interaction studies - 4 Nov 2005

Second Scienceletter: Effects of flavonoids on the P-Glycoprotein activity - 20 Sep 2005

Our first Scienceletter: Efflux transporters: boon or blight for big pharma? - 24 Aug 2005


To subscribe to SOLVO's newsletter/scienceletter please enter the following data:

Your name:
Your company:
E-mail address:
Type: Newsletter:
Scienceletter:
Visual CAPTCHA
Enter visual code:
This page contains information about following topics: Verapamil, Transporter drug-drug interaction, Transporter Oral bioavailability, BBB penetration, Transporter CNS, Intestinal Drug Absorption.
This page contains information about following topics: Verapamil, Transporter drug-drug interaction, Transporter Oral bioavailability, BBB penetration, Transporter CNS, Intestinal Drug Absorption.